'Absent or Trivial' Effects: Anti-Amyloid Alzheimer's Drugs Called into Question Again

Top drugmakers have spent more than a decade investigating and advancing anti-amyloid Alzheimer's medicines in clinical studies, generating enough evidence to support FDA approvals for three of them so far. But a new analysis throws more cold water on the treatment approach after years of doubts, and some successes. Medicines in this class, which include Biogen and Eisai's Leqembi and Eli Lilly's Kisunla, "likely have no clinically meaningful positive effects," according to a press release from the nonprofit health research organization Cochrane. Further, the meds likely increase the risk of brain swelling, the group's review found.